S103
Brachytherapy - Head & neck, skin, eye
ESTRO 2026
Results: Of 231 screened studies, 38 were included in full-text screening and 18 in the analyses, which described 4186 patients in total. 6 studies were from centers that treated ≥ 30 patients per year (high ATV group), while 12 centers treated <30 patients per year (low ATV group). There was a wide variety in indications and treatment regimens (table 1). The pooled estimate 5- year local failure risk was 9.3% for the full cohort, and was 4.1% in centers with a high ( ≥ 30 patients) vs 15.2% in those with a low (<30) annual treatment volume (p<0.001, figure 1). When a cutoff of 50 treated patients yearly was used, the difference between groups remained statistically significant (5.1% vs 11.3%, p=0.049). Notably, some low-volume centers also achieve high rates of local control, e.g. by integrating UM care into broader head-and-neck tumor boards or through staff exchange with high- volume institutions, demonstrating that high treatment volume is not an absolute prerequisite for successful outcomes.
control at five years after ruthenium-106 brachytherapy for uveal melanoma varies little (92- 99%) and is significantly higher (96%) than in centers with a lower ATV (84%, 58-97%), although some specific low-ATV centers also reported high local control rates. Thus, local control rate is high in all centers with a high annual treatment volume and in some centers with a lower annual treatment volume. Keywords: Uveal Melanoma, Ru-106, Annual treatment volume Digital Poster 4214 Contact Brachytherapy Protocol for the Management of Primary Cutaneous Follicular Center B-Cell and Primary Cutaneous Marginal Zone B-Cell Lymphomas Susana Perez Echaguen 1 , Camilo Jose Sanz Freire 2 , Katty Zavala Aguilar 1 , Marta Labado Mora 1 , Gustavo Adolfo Ossola Lentati 1 1 Radiation Oncology, CIBIR-San Pedro Hospital, Logroño, Spain. 2 Medical Physics, CIBIR-San Pedro Hospital, Logroño, Spain Purpose/Objective: Primary cutaneous B-cell lymphomas (PCBCLs) are highly radiosensitive, with local radiotherapy (EBRT) as the treatment of choice. Photon-based EBRT is used for large, irregular, or anatomically complex lesions, whereas superficial lesions are traditionally treated with 6–9 MeV electron beams, often with bolus application and shielding for organs at risk (e.g., eyes, oral commissure, ear). This study evaluates contact brachytherapy as an alternative to electron beam therapy in selected T1–T2 PCBCLs. Material/Methods: Following the 2018 upgrade of our linear accelerators, we discontinued electron EBRT. We began with a patient presenting a localized cutaneous lymphoma <5 mm in thickness—traditionally treated with electrons. Based on our experience with non-melanoma skin cancers using HDR contact brachytherapy with customized molds, we treated the patient with contact brachytherapy. Dosimetry, treatment tolerability, reproducibility, oncologic outcomes, acute and late toxicity, and organ-at-risk sparing were compared to expected electron beam results. Prescribed doses followed international guidelines: 30 Gy in conventional fractionation (2 Gy/session, five sessions/week). Mold fabrication and dosimetric characterization of the material have been reported previously [1].
Table 1 *One study described two groups from different time-periods
Figure 1 Conclusion: In centers with a high annual treatment volume, local
Made with FlippingBook - Share PDF online